Literature DB >> 31241921

Synthesis, Structure, Stability, and Inhibition of Tubulin Polymerization by RuII-p-Cymene Complexes of Trimethoxyaniline-Based Schiff Bases.

Sourav Acharya1, Moumita Maji1, Kallol Purkait1, Arnab Gupta2, Arindam Mukherjee1,3.   

Abstract

Four trimethoxy- and dimethoxyphenylamine-based Schiff base (L1-L4)-bearing RuII-p-cymene complexes (1-4) of the chemical formula [RuII(η6-p-cymene)(L)(Cl)] were synthesized, isolated in pure form, and structurally characterized using single-crystal X-ray diffraction and other analytical techniques. The complexes showed excellent in vitro antiproliferative activity against various forms of cancer that are difficult to cure, viz., triple negative human metastatic breast carcinoma MDA-MB-231, human pancreatic carcinoma MIA PaCa-2, and hepatocellular carcinoma Hep G2. The 1H nuclear magnetic resonance data in the presence of 10% dimethylformamide-d7 or dimethyl sulfoxide-d6 in phosphate buffer (pD 7.4, containing 4 mM NaCl) showed that the complexes immediately generate the aquated species that is stable for at least 24 h. Electrospray ionization mass spectrometry data showed that they do not bind with guanine nitrogen even in the presence of 5 molar equivalents of 9-EtG, during a period of 24 h. The best complex in the series, 1, exhibits an IC50 of approximately 10-15 μM in the panel of tested cancer cell lines. The complexes do not enhance the production of reactive oxygen species in the cells. Docking studies with a tubulin crystal structure (Protein Data Bank entry 1SAO ) revealed that 1 and 3 as well as L1 and L3 have a high affinity for the interface of the α and β tubulin dimer in the colchicine binding site. The immunofluorescence studies showed that 1 and 3 strongly inhibited microtubule network formation in MDA-MB-231 cells after treatment with an IC20 or IC50 dose for 12 h. The cell cycle analysis upon treatment with 1 showed that the complexes inhibit the mitotic phase because the arrest was observed in the G2/M phase. In summary, 1 and 3 are RuII half-sandwich complexes that are capable of disrupting a microtubule network in a dose-dependent manner. They depolarize the mitochondria, arrest the cell cycle in the G2/M phase, and kill the cells by an apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31241921      PMCID: PMC7165017          DOI: 10.1021/acs.inorgchem.9b00853

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  57 in total

1.  N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.

Authors:  Helge Prinz; Ann-Kathrin Ridder; Kirsten Vogel; Konrad J Böhm; Igor Ivanov; Jahan B Ghasemi; Elham Aghaee; Klaus Müller
Journal:  J Med Chem       Date:  2017-01-13       Impact factor: 7.446

2.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

Review 3.  Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

Authors:  A Bergamo; C Gaiddon; J H M Schellens; J H Beijnen; G Sava
Journal:  J Inorg Biochem       Date:  2011-09-29       Impact factor: 4.155

Review 4.  Indole, a core nucleus for potent inhibitors of tubulin polymerization.

Authors:  Andrea Brancale; Romano Silvestri
Journal:  Med Res Rev       Date:  2007-03       Impact factor: 12.944

Review 5.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

6.  Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.

Authors:  Anna F A Peacock; Abraha Habtemariam; Rafael Fernández; Victoria Walland; Francesca P A Fabbiani; Simon Parsons; Rhona E Aird; Duncan I Jodrell; Peter J Sadler
Journal:  J Am Chem Soc       Date:  2006-02-08       Impact factor: 15.419

7.  A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo.

Authors:  Wai-Lun Kwong; Kar-Yee Lam; Chun-Nam Lok; Yau-Tsz Lai; Pui-Yan Lee; Chi-Ming Che
Journal:  Angew Chem Int Ed Engl       Date:  2016-09-26       Impact factor: 15.336

8.  The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway.

Authors:  Isolda Romero-Canelón; Luca Salassa; Peter J Sadler
Journal:  J Med Chem       Date:  2013-01-31       Impact factor: 7.446

Review 9.  Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.

Authors:  Anna F A Peacock; Peter J Sadler
Journal:  Chem Asian J       Date:  2008-11-13

Review 10.  Metal complexes in cancer therapy - an update from drug design perspective.

Authors:  Umar Ndagi; Ndumiso Mhlongo; Mahmoud E Soliman
Journal:  Drug Des Devel Ther       Date:  2017-03-03       Impact factor: 4.162

View more
  2 in total

1.  Is the Way to Fight Cancer Paved with Gold? Metal-Based Carbene Complexes with Multiple and Fascinating Biological Features.

Authors:  Domenico Iacopetta; Camillo Rosano; Marco Sirignano; Annaluisa Mariconda; Jessica Ceramella; Marco Ponassi; Carmela Saturnino; Maria Stefania Sinicropi; Pasquale Longo
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-11

2.  Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes.

Authors:  Christopher Wittmann; Anastasiia S Sivchenko; Felix Bacher; Kelvin K H Tong; Navjot Guru; Thomas Wilson; Junior Gonzales; Hartmut Rauch; Susanne Kossatz; Thomas Reiner; Maria V Babak; Vladimir B Arion
Journal:  Inorg Chem       Date:  2022-01-07       Impact factor: 5.165

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.